ArticleEuropean archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery2026
Characterizing risk groups in papillary thyroid carcinoma through T-Cell mediated tumor cell killing-related genes: a pathway to therapeutic predictions.
Article in European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAlthough immune checkpoint inhibitors show promise in papillary thyroid carcinoma (PTC), their efficacy is limited by immune resistance. This study constructed a prognostic model based on genes associated with the sensitivity of tumor cells to T cell-mediated tumor killing (GSTTKs) to evaluate their role in prognostic prediction for PTC.
methodsDifferentially expressed genes between PTC and normal tissues were identified from the TCGA dataset and intersected with GSTTKs to obtain TTK-related differentially expressed genes. A prognostic model was constructed through regression analysis, and predictive performance was evaluated using ROC curves. The impact of model genes on the malignant progression of PTC was validated through cell experiments, and the regulatory relationship between key transcription factors and target genes was verified using ChIP-qPCR.
resultsA prognostic model constructed based on five TTK-related genes (including B3GLCT, EPS15L1, and FGFR4) exhibited robust predictive performance in PTC. EPS15L1, P2RY11, and B3GLCT may serve as candidate therapeutic targets for PTC, whereas knockdown of PSORS1C1 repressed malignant progression of PTC cells under the transcriptional regulation of PRDM10.
conclusionA prognostic model built on genes associated with intrinsic T-cell killing sensitivity of tumor cells enables risk stratification of PTC patients independent of immune cell infiltration abundance, and the identified drug-target interactions as well as the PRDM10/PSORS1C1 regulatory axis offer novel insights for precision therapy.
Indexed as
Identifiers
42507215What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.